Garde Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Garde Capital’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-750	Closed	-$180	–	245
2025 Q2	$180	Buy	+750	New	+$200	﹤0.01%	796

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Garde Capital's ADAP Position: Q3 2025 in Review

Garde Capital sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 750 shares — an estimated $180 sold.

Garde Capital first reported a position in ADAP in Q2 2025 and held it in 1 quarter. The position peaked at $180 in Q2 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Garde Capital reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 750 Adaptimmune Therapeutics shares in Q3 2025, an estimated $180.
Garde Capital first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 1 quarter.
Garde Capital's Adaptimmune Therapeutics position peaked at $180 in Q2 2025.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.